2019 Annual Report
Today we are publishing our 2019 Annual Report, covering a year of regional growth, increased localisation of strategies, and the development of two new teams; Organisational Development and Impact Investing.
In 2019, we continued to put children and adolescents at the heart of every programme. We developed a new Africa Strategy, opened an office in Beijing, China, and substantially strengthened our team in Addis Ababa, Ethiopia. These steps furthered our efforts to empower local change-makers to deliver systemic change in their own communities.
“In 2019, we continued to invest in delivering near-term, measurable and ambitious outcomes that improve children’s lives, as well as working towards the long-term security of children’s futures.” – Dr Graeme Sweeney, Chair, Children’s Investment Fund Foundation
Over the course of 2019, we approved $386 million in new charitable investments (a rise of $64 million over 2018) and $269 million was disbursed between our Addis Ababa, Beijing, Delhi, London and Nairobi offices. See a selection of key portfolio highlights from last year below:
- Clean Air Fund, an organisation working to improve air quality across the globe, was formally launched at the United Nations General Assembly in September, with the support of $20 million from CIFF.
- The Healthy Mothers, Healthy Babies Accelerator was launched in 2019, to advance the uptake of multiple micronutrient supplements (MMS). CIFF alongside funding partners will collectively invest roughly $50 million into the Accelerator over the next three years, to support over 17.5 million pregnant women access MMS.
- Over 1900 traffickers were identified through the Mukti Caravan (Freedom Van) Campaign by CIFF-funded Kailash Satyarthi Children’s Foundation in India. Mukti Caravan is a nationwide campaign on wheels against the organised crime of child trafficking.
- CIFF worked with grantees to expand the availability of self-care tools and broaden the adoption of youth-led design for future SRH programmes. Major progress was made on DMPA-SC (a type of self-injectable contraceptive), a ‘dual-pill’ for HIV and pregnancy prevention, and HIV self-testing with dozens of countries supporting scale-up.
To view the Annual Report in full, click below.